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Abstract We measured IgA and IgG antibodies to pertussis
toxin (PT) and filamentous hemagglutinin (FHA) in sera
from 203 1-year-old children who had received one to three
doses of a monocomponent PT toxoid vaccine. Ten children
(5%) had IgA antibody to PT indicating recent infection;
seven of these children had received three doses of vaccine.
PT IgA responders did not have significantly longer
coughing episodes than PT IgA non-responders. Since an
IgA antibody response occurs in only ∼50% of infected
children, the actual infection rate in our cohort is estimated
to ∼10%. The apparent high Bordetella pertussis infection
rate in Danish infants suggests that the monocomponent
PT toxoid vaccine used in Denmark has limited efficacy
against B. pertussis infection. A prospective immunization
study comparing a multi-component vaccine with the present
monocomponent PT toxoid vaccine should be undertaken.
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Pertussis epidemiology
Introduction
Despite high vaccination coverage, pertussis continues to
be a major cause of morbidity and mortality in Europe [16].
The clinical spectrum is diverse and is affected by patient
age, previous exposure to the organism and immunization
history [2, 3, 11]. The heterogeneity in pertussis disease
expression makes it an often unrecognized and undiagnosed
disease. Pertussis appears epidemically every 2 to 5 years.
However, epidemiological data are incomplete, and different
reporting procedures suggest that only the tip of the iceberg
is evident [2, 3, 11, 16]. Improved disease surveillance and
diagnoses are essential to determine the true burden of the
disease.
The situation in Denmark is unique in that all children
are vaccinated with a domestically produced DTaP (Di-Te-
Kik) vaccine in which toxoided pertussis toxin (PT) is the
only pertussis component. The PT toxoid vaccine replaced
the whole-cell pertussis vaccine in January 1997. The PT
toxoid vaccine is reported to provide about 78% protection
against notified pertussis after three vaccinations given at
3, 5 and 12 months of age as part of the national child
immunization program [9]. Vaccination effectiveness for
two doses of pertussis toxoid vaccine in the first year of life
is reported to be 59%. In September 2003, a pre-school
pertussis booster vaccination at 5 years of age was
implemented to reduce transmission to susceptible young
children. Infection results in IgA and IgG antibody
responses to specific Bordetella pertussis antigens, whereas
vaccination results in only an IgG response to these
antigens [3, 11].
Diagnosis of pertussis based on clinical symptoms is
complicated by a number of factors: the wide spectrum of
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symptoms of other infections [2, 3, 11, 16]. A WHO
committee in 1991 developed a primary case definition to be
used in vaccine efficacy trials: An illness with paroxysmal
cough of ≥21 days and either culture-confirmed infection
with B. pertussis or serological evidence of infection with
B. pertussis or household contact with a case of culture-
confirmed pertussis with onset of cough within 28 days
before or after onset of cough [21].
In the present study, we investigated whether there was
evidence of circulation of B. pertussis in the community.
This would provide baseline data on which to assess the
epidemiology of B. pertussis and thus direct future use of
pertussis vaccines in Denmark.
Methods
Study subjects The study population consisted of healthy
children enrolled from the postnatal ward at Hvidovre
Hospital, Denmark during a 12-month period from May
2004 to May 2005 [19]. Children were originally enrolled
for the study of human metapneumovirus and respiratory
syncytial virus infections in infancy. Approximately 20
children were enrolled each month to ensure that the
children were sampled equally throughout the year. A total
of 242 healthy newborns were enrolled, of whom 217 were
followed throughout 1 year.
Study procedures Children were monitored with detailed
health diaries and through monthly home visits until 1 year
of age. The study procedures have been previously
described in detail [19]. The children were scheduled to
receive routine immunizations with D-T-aP-IPV-Hib at 3, 5
and 12 months of age. Blood samples were obtained by
venous puncture from 203 of the children at age 12 months
and the sera kept at −80°C until further analysis.
Laboratory assays Twofold dilutions of 50 µl of serum
were used for the pertussis ELISA. IgA and IgG antibodies
to PTand filamentous hemagglutinin (FHA) were measured
by a standardized ELISA procedure and expressed in
ELISA units (EU/ml) with respect to reference serum 3 of
the Center for Biologics Evaluation and Research/US Food
and Drug Administration (CBER/FDA) [20]. The lower
levels of detection for the assays were 1.7 EU/ml for IgG-
anti-PT, 2.4 EU/ml for IgA-anti PT, 1.8 EU/ml for IgG-anti-
FHA and 1.7 EU/ml for IgA-anti-FHA.
Statistical analysis Antibody concentrations and prevalence
were tabulated. For differences in duration in days of
coughing episodes and in infants with IgA positive and IgA
negative samples, the Mann–Whitney rank sum was used.
Results
At the time of blood sampling, 100% of children had
received one dose, 98% had received two doses and 23%
had received three doses of the PT toxoid vaccine. Because
IgA antibodies are a result of infection and not vaccination,
we used their presence as an indicator of infection in the
study children. Ten children (4.9%) had IgA antibody to
PT, 18 (8.9%) had IgG antibody to FHA, 193 (95.1%) had
IgG antibody to PT and 13 (6.4%) had IgA antibody to
FHA. Seven of the ten PT IgA responders had received
three doses of vaccine and the remaining three PT IgA
responders had received two doses at 3 and 5 months of
age.ThemedianPTIgGtiterforfullyvaccinatedchildrenwas
50EU/ml vs.8EU/ml forchildrenwhohadonlyreceivedone
or two doses of the PT toxoid vaccine (p<0.001).
Clinical data on cough were obtained from the health
diaries of the study subjects and are illustrated in Table 1.
PT IgA responders did not have significantly longer
coughing episodes during the first year of life than IgA
non-responders (median 11.5 days vs. 10.0 days, p=0.186).
However, two (20%) of IgA responders had cough for more
than 21 days compared to 27 (14%) of IgA non-responders
(p=>0.05). Mean age at longest coughing episode was
7.5 months. In one PT IgA positive and 20 PT IgA negative
children, the longest coughing episode was associated with
wheezing, suggesting a viral infection and not B. pertussis
infection as the cause of the illnesses. Excluding these 21
children from analysis did not alter the main results (median
duration of cough 11 vs. 9 days, p=0.209). No differences in
other symptoms such as fever, rash, diarrhea and vomiting
were observed between the groups (data not shown).
Discussion
Infection with B. pertussis stimulates both IgA and IgG
antibody responses to B. pertussis antigens. In an efficacy
Table 1 Duration of longest coughing episode during the first year of
life in 203 Danish children related to PT IgA antibody status
Duration of cough PT IgA pos
(n=10) (%)
PT IgA neg
(n=193) (%)
<7 days 2 (20) 59 (30.6)
7–14 days 4 (40) 89 (46.1)
15–21 days 2 (20) 18 (9.3)
22–28 days 1 (10) 8 (4.1)
29–35 days 0 11 (5.7)
36–42 days 0 3 (1.6)
43–49 days 1 (10) 2 (1.0)
>49 days 0 3 (1.6)
1120 Eur J Pediatr (2010) 169:1119–1122trial [12] in Germany, only 120 (52%) of 232 children with
pertussis had an IgA response to PT (Heininger and Cherry
unpublished data 1998). We found serological evidence of
B. pertussis infection (IgA PT antibody) in 5% of our
cohort of vaccinated healthy children during their first year
of life. Since only 50% of infections result in a PT IgA
antibody response, the actual infection rate in our cohort
may have been ∼10%. It is of interest that seven of 47
(15%) with three doses of vaccine had a PT IgA antibody
response, whereas only three of the 156 (2%) who had less
than three doses of vaccine had a PT IgA antibody
response. The explanation for this observation is that once
a natural infection has occurred, immunization will enhance
the PT IgA response. This was observed following the
fourth dose in the German efficacy trial mentioned above
[12] as well as in a more recent adult vaccine efficacy trial
[10]. The presence of IgG and IgA antibodies to FHA in
8.9% and 6.4%, respectively, in the serum of study subjects
is also an indicator of B. pertussis infection since the
vaccine did not contain this antigen. However, antibody to
FHA in contrast to antibody to PT is less specific. Infection
with other Bordetella sp. as well as other gram negative
bacteria may stimulate an antibody response to FHA [18].
Illnesses with cough are common during infancy. The
duration of the most significant cough illness in our study
subjects with evidence of B. pertussis infection was not
significantly different from the duration in subjects without
evidence of B. pertussis infection. This observation suggests
that the infections that occurred in the previous vaccinees
were clinically mild.
With the exception of the DTaP vaccine (Di-Te-Kik) in
use in Denmark, which contains only toxoided PT as the
pertussis component, the DTaP vaccines presently in use
throughoutthe worldcontaintoxoidedPTaswellas1–4ot he r
B. pertussis antigens (FHA, pertactin [PRN] and fimbriae 2/3
[FIM 2/3]) [3, 11]. The reported pertussis vaccine efficacy in
the 1980s and 1990s trials varied considerably based on the
case definition used [3–7, 11–15, 17].
The main objection to the WHO primary case definition
of pertussis is that it eliminated many laboratory-confirmed
clinically mild cases from efficacy calculations in vaccine
trials. Because mild cases are more common in vaccinees
than in controls, efficacy is inflated. Therefore, vaccine
efficacy appears better than it truly is, and less effective
vaccines would also seem comparable with their more
effective counterparts. Results from a randomized trial of
acelluar pertussis vaccines in Stockholm in the 1980s
showed that significantly fewer recipients of a two-
component vaccine (JNIH-6) were diagnosed as primary
or co-primary cases in households than those who received
a monocomponent vaccine (JNIH-7) [13]. Regarding the
Danish PT toxoid vaccine (Di-Te-Kik), it was used
exclusively in the Gothenburg region of Sweden from
1996 until the spring of 1999. The rate of pertussis (in
children born between January 1996 and June 1999)
between October 1997 and September 2004 was deter-
mined for children in the Gothenburg region and the rest of
Sweden [1, 8]. The rate of pertussis (mostly vaccine
failures) in the Gothenburg region was significantly higher
in all children less than 8 years than the rate in the rest of
Sweden, where a three component DTaP vaccine was
predominantly used.
In conclusion, our data indicate that 5–10% of our
vaccinated cohort of healthy children had a B. pertussis
infection during the first year of life, demonstrating that
B. pertussis is circulating in the community even though
few clinical cases were recognized. The high B. pertussis
infection rate in Danish infants as well as the surveillance
data from Sweden suggest that the PT toxoid vaccine used
in Denmark has less than optimal efficacy. A prospective
immunization study comparing a multi-component vaccine
with the present monocomponent PT toxoid vaccine should
be undertaken.
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